How do Phase 2 clinical trials test whether a drug works for a particular condition?

Phase 2 clinical trials are a critical stage in the development of new drugs. Unlike Phase 1 studies, which primarily focus on safety and dosage in a small group, Phase 2 trials involve a larger cohort, typically consisting of 50 to 150 subjects.1

The primary objective of a Phase 2 trial is to evaluate the effectiveness of an intervention for a specific, well-defined medical condition. Researchers assess how well the drug works for that condition while simultaneously monitoring the side effects experienced by the participants.1

By testing the drug in a population that actually has the target disease, investigators can determine if the treatment shows enough promise to justify moving forward to Phase 3, where it would be directly compared against standard treatments or a placebo. Throughout this process, the safety and well-being of participants remain paramount, governed by strict ethical standards such as the Declaration of Helsinki to ensure informed consent and appropriate risk management.1